The Mycophenolate Pregnancy Registry was introduced to assess risks and outcomes associated with mycophenolate use during pregnancy – a situation that occurs far too often, despite boxed warnings and an ongoing REMS program.
In this second of two, interactive …
The Mycophenolate Risk Evaluation and Mitigation Strategy (MREMS) was initiated in 2012, yet more than a decade later prenatal exposure to mycophenolate, an immunosuppressive agent with significant teratogenicity, continues to occur at unacceptably high rates. While the MREMS provides direction …
Food insecurity and nutritional inequity disproportionately impact underserved communities. These disparities are directly linked to higher rates of chronic diseases, such as obesity, diabetes, and cardiovascular diseases. Research shows that access to healthy food is limited in food deserts, exacerbating …
Food insecurity and other negative social drivers of health (SDOH) impact health outcomes in underserved Black communities. Screening for food insecurity using validated tools has proven to be an essential part of healthcare interventions to connect patients to critical resources, …
Inequitable distribution of and access to healthy food exacerbates chronic conditions such as obesity, diabetes, and cardiovascular diseases for low-income and non-White communities. Research shows that the absence of affordable, healthy food options, combined with social drivers of health like …
Treatment guidelines for chronic inflammatory demyelinating polyneuropathy (CIDP), an autoimmune neuro-muscular condition impacting the myelin that insulates and protects peripheral nerves causing mobility and sensory impairment, have been in place for many years with new treatment approvals being scarce. Newly …
Crohn’s disease (CD) can cause progressive bowel damage, impaired quality of life, and permanent disability. Severity and presentation can vary widely from person to person, necessitating an individualized treatment approach. The use of more readily available imaging modalities such as …
Cytokines, such as interleukin (IL)-23, are key drivers of intestinal inflammation in patients with inflammatory bowel disease. While all IL-23–targeted agents neutralize IL-23, differences in antibody structure can improve the ability of these agents to capture this inflammatory cytokine from …
Recent advances in the treatment of gynecologic cancers are promising, and education is needed to ensure that both oncology and primary care clinicians, including OB/GYNs, have a thorough knowledge of biomarkers, current and emerging therapies, and how the latest clinical …